Transplantační medicína

Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.

Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.

Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.

Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.

Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.

Prof Bonifacio discusses the predictive value and utility of islet autoantibodies as biomarkers of the risk and rate of progression to clinical T1D 

Prof. Wentworth discusses how T1D risk prediction can be improved through the development of tools that integrate multiple risk factors and biomarkers 

Profs. Kay and Bonifacio discuss the role of T-cell dysregulation as a central pathophysiological mechanism in T1D, and its implications for emerging therapies and biomarkers

Gaucher disease is a lysosomal storage disorder caused by a pathogenic variant in the gene responsible for producing the enzyme acid β-glucosidase. More than 300 alleles carrying pathogenic variants have already been identified.¹

Gaucher disease is rare and has signs and symptoms that can be confused with those of many other diseases. However, some tests allow the definitive diagnosis of the disease.

Gaucher disease is rare and has signs and symptoms that can be confused with those of many other diseases. However, some tests allow the definitive diagnosis of the disease.